I'm "pretty sure" that PR implies that the Data Safety Monitoring Committee (“DSMC”) will perform the interim analysis, not CYDY employees. Although my confidence with interpreting CYDY PR wording is a bit shaky lately.

Per the linked FDA document, the idea is that the trial sponsor (CYDY) should not get a premature peek at any efficacy data before the trial ends, otherwise the the sponsor could become biased and the eventual trial results could be considered compromised.